多孔钽涂层与非多孔钽涂层髋臼组件在翻修全髋关节置换术后再翻修风险中的比较:来自英格兰和威尔士国家关节登记系统的倾向性评分匹配研究
基于英格兰和威尔士国家关节登记系统数据,回顾性纳入同一厂商四种非骨水泥髋臼组件的翻修全髋关节置换术,经倾向性评分匹配为多孔钽组与非多孔钽组各1931例;两组6年全因再翻修、无菌性松动再翻修及感染再翻修率均相似,初始因感染翻修的亚组中两组再翻修率亦相似。
要点
- 匹配后多孔钽组与非多孔钽组各1931例翻修全髋关节置换术,总体髋臼再翻修率为2.7%(95%CI=2.1%至3.2%)。
- 6年全因再翻修率两组相似(SHR=0.91;95%CI=0.61至1.35;p=0.636)。
- 初始因感染翻修的247例亚组中,两组再翻修率亦相似(全因再翻修SHR=0.48;95%CI=0.15至1.56;p=0.225)。
核心结论
- 翻修全髋关节置换术后,多孔钽涂层髋臼组件的无菌性和感染性再翻修风险均低,与非多孔钽组件相当。
- 需对大型翻修全髋关节置换术队列进行延长随访,以确定多孔钽组件在髋臼骨量相似患者中是否较非多孔钽设计具有临床获益。
研究设计与样本
- 回顾性观察性研究,纳入英格兰和威尔士国家关节登记系统中使用同一厂商(Zimmer Biomet)四种非骨水泥髋臼组件的所有翻修全髋关节置换术。
- 髋臼组件分为多孔钽表面涂层(TM Modular和Continuum设计)与非多孔钽表面涂层(Trilogy和Trilogy IT设计)。
- 采用倾向性评分对多孔钽与非多孔钽植入物进行匹配,以控制多个潜在患者和手术混杂因素。
- 采用竞争风险回归分析比较匹配组间翻修全髋关节置换术后的结局(全因髋臼指征再翻修、无菌性髋臼松动或感染)。
- 在初始因感染翻修的亚组中重复分析。
主要发现
- 匹配后共3862例翻修全髋关节置换术(多孔钽组1931例,非多孔钽组1931例),总体髋臼再翻修率为2.7%(95%CI=2.1%至3.2%)。
- 无菌性髋臼松动再翻修率为0.96%(95%CI=0.68%至1.3%),感染再翻修率为1.4%(95%CI=1.0%至1.8%)。
- 6年全因再翻修率两组相似(SHR=0.91;95%CI=0.61至1.35;p=0.636)。
- 6年无菌性髋臼松动再翻修率两组相似(SHR=1.32;95%CI=0.68至2.53;p=0.410),感染再翻修率两组相似(SHR=0.68;95%CI=0.39至1.20;p=0.165)。
- 初始因感染翻修的247例全髋关节置换术(多孔钽组116例,非多孔钽组131例)中,全因再翻修率(SHR=0.48;95%CI=0.15至1.56;p=0.225)、无菌性髋臼松动再翻修率(SHR=0.54;95%CI=0.05至5.74;p=0.608)和感染再翻修率(SHR=0.82;95%CI=0.28至2.36;p=0.706)两组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies have suggested that Trabecular Metal (TM)-coated acetabular components may reduce implant failure following revision total hip arthroplasty. However, these studies have predominantly been limited to small, single-center cohorts, with many lacking a comparator group. Using National Joint Registry data from England and Wales, we compared re-revision rates following revision total hip arthroplasty between TM and non-TM-coated acetabular components from 1 manufacturer. METHODS: This retrospective observational study included all revision total hip arthroplasties performed with use of 1 of 4 cementless acetabular components produced by the same manufacturer (Zimmer Biomet). The acetabular components either had a TM surface coating (TM Modular and Continuum designs) or a non-TM surface coating (Trilogy and Trilogy IT designs). Revision total hip arthroplasties with TM and non-TM implants were matched for multiple potential patient and surgical confounding factors using propensity scores. Outcomes following revision total hip arthroplasty (re-revision for all acetabular indications, aseptic acetabular loosening, or infection) were compared between matched groups using competing risk regression analysis. Analyses were repeated in a subgroup initially revised for infection. RESULTS: Of 3,862 matched revision total hip arthroplasties (1,931 in the TM group and 1,931 in the non-TM group), the overall prevalence of acetabular re-revision (2.7%; 95% confidence interval [CI] = 2.1% to 3.2%), re-revision for aseptic acetabular loosening (0.96%; 95% CI = 0.68% to 1.3%), and re-revision for infection (1.4%; 95% CI = 1.0% to 1.8%) were low. Six-year rates of re-revision for all causes (subhazard ratio [SHR] = 0.91; 95% CI = 0.61 to 1.35; p = 0.636), aseptic acetabular loosening (SHR = 1.32; 95% CI = 0.68 to 2.53; p = 0.410), and infection (SHR = 0.68; 95% CI = 0.39 to 1.20; p = 0.165) were similar between revision total hip arthroplasties with TM and non-TM coatings. Of 247 total hip arthroplasties initially revised for infection (116 TM and 131 non-TM), the rates of re-revision for all causes (SHR = 0.48; 95% CI = 0.15 to 1.56; p = 0.225), aseptic acetabular loosening (SHR = 0.54; 95% CI = 0.05 to 5.74; p = 0.608), and infection (SHR = 0.82; 95% CI = 0.28 to 2.36; p = 0.706) were similar between the TM and non-TM groups. CONCLUSIONS: Following revision total hip arthroplasty, TM-coated acetabular components had a low risk of both aseptic and septic re-revision, with rates that were comparable with those of non-TM components. Extended follow-up of large revision total hip arthroplasty cohorts will establish whether TM components have any clinical benefit over non-TM designs when used in patients with similar acetabular bone stock. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Matharu GS, Judge A, Murray DW, et al. Trabecular Metal Versus Non-Trabecular Metal Acetabular Components and the Risk of Re-Revision Following Revision Total Hip Arthroplasty: A Propensity Score-Matched Study from the National Joint Registry for England and Wales. J Bone Joint Surg Am. 2018. PMID: 29975265. doi:10.2106/JBJS.17.00718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。